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Background:  Chronic  hepatitis  C  is a major  cause  of liver-associated  mortality  caused  by decompen-
sated  cirrhosis  and hepatocellular  carcinoma.  With the  approval  of  sofosbuvir,  therapeutic  efﬁcacy  has
markedly increased.  Early  changes  in non-invasive  biomarkers  of  liver  ﬁbrosis  under  effective  antiviral
therapy  are  widely  unknown.
Aim:  To  evaluate  early  changes  of ﬁbrosis  markers  determined  by enhanced  liver  ﬁbrosis  (ELF)  scores  and
liver stiffness  measurement  (FibroScan®)  in  patients  treated  with  sofosbuvir.
Methods:  A  total of  32  hepatitis  C patients  treated  prospectively  with  sofosbuvir  were  included.  The  ELF-
panel  and  FibroScan  measurements  were  performed  at baseline,  week  4, end-of-treatment  and  12  weeks
thereafter.
Results:  Antiviral  therapy  resulted  in  a biochemical  and  virological  response  within  4 weeks.  Sustained
virological  response  rate  at 12-week  follow-up  (SVR12)  was  93.8%;  there  was  a  signiﬁcantly  decrease
from  baseline  to 12-week  post-treatment  follow-up  in  ELF (10.00  vs.  9.37;  p = 0.007)  and  FibroScan  (8.0
vs.  6.8  kPa;  p  =  0.016)  measurements,  indicating  improvement  of  the  dynamics  of liver ﬁbrosis.
Conclusion:  We  observed  a rapid decrease  in  non-invasive  ﬁbrosis  markers  measured  by ELF-scores  and
FibroScan  in  hepatitis  C-infected  patients  receiving  sofosbuvir  treatment.  These  initial  results  need to  be
histologically  conﬁrmed  by liver  biopsy  in the  future.
©  2015  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. Introduction
Chronic hepatitis C virus (HCV) associated with end stage liver
isease is still a major cause of liver-related mortality worldwide,
ince currently approximately 25% of primary hepatocellular carci-
omas (HCC) and 25% of liver cirrhosis are due to chronic hepatitis
 (CHC) [1].
∗ Corresponding author at: I. Department of Medicine, Cirrhosis Center Mainz
CCM), Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55101 Mainz,
ermany. Tel.: +49 06131 17 6073; fax: +49 06131 17 476075.
E-mail address: tim.zimmermann@unimedizin-mainz.de (T. Zimmermann).
1 These authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.dld.2015.09.015
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. AllIf untreated, HCV infection leads to cirrhosis in a quarter of
patients over a period of 20–30 years, while successful antivi-
ral therapy with a sustained virological response (SVR) results in
a reduction of liver-related morbidity and mortality including a
lower incidence of HCC and a reduced need for liver transplant
[2,3].
In 2014, the ﬁrst NS5B RNA-polymerase inhibitor sofosbuvir
was approved for the treatment of HCV-infection in conjunction
with pegylated Interferon- (Peg-IFN) and/or ribavirin, yielding
high SVR rates of around 90% after short-term therapy in genotype
1–3-infected patients [4,5].
In the present study, we aimed to evaluate early changes
of dynamic ﬁbrosis-related parameters using the enhanced liver
ﬁbrosis (ELF) panel, combined with liver stiffness measurement
 rights reserved.
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LSM), and metabolic alterations in insulin resistance, lipid and
ron metabolism during highly effective sofosbuvir-based antiviral
herapy [6–14].
A few studies and meta-analyses from recent years demonstrate
igh accuracy of ELF and LSM in detecting liver ﬁbrosis and treat-
ent effects in patients with chronic hepatitis C and B [10–14]. ELF
nd LSM especially showed similar results with high correlation to
iver biopsy [10–14].
. Materials and methods
.1. Patients
From February to July 2014, all patients with CHC who
nderwent antiviral therapy at the 1st Department of Medicine
t the University Medical Centre Mainz were enrolled in this
rospective study consecutively. All individuals were treated
ith a Sofosbuvir-based treatment regimen, in combination with
imeprevir (n = 4)/pegylated interferon (PEG-IFN, n = 19) and/or
ibavirin (RBV, n = 29). Only four patients received a 24-week ther-
py, and the majority (n = 28) were treated within a window of 12
eeks. Patients were assessed at week 0 (baseline), at week four,
t end of treatment (EoT), and at 12-week post-treatment follow-
p. Undetectable HCV RNA at 12-week follow-up was  deﬁned as
VR12.
This study was approved by the Institutional Review Board
f Mainz University Medical Centre (no. 837.199.10/7208) and
onducted in accordance with the Declaration of Helsinki and
ood Clinical Practice guidelines. Written informed consent was
btained from each patient before enrolment.
.2. ELF-score and APRI measurements
The ELF-score, which consists of an algorithm of age, serum
rocollagen type III amino terminal propeptide (PIIINP), tissue
nhibitor of metalloproteinases-1 (TIMP-1) and hyaluronic acid
HA) (ADVIA Centaur CP System, Siemens Healthcare Diagnos-
ics, Eschborn, Germany) and the APRI (AST-platelet-ratio-index)
ere measured in blood samples at weeks 0, 4, EoT, and SVR12
8,9,15,16].
ELF categorizes liver ﬁbrosis according to three levels of sever-
ty: none to mild (METAVIR F0-1, <7.7), moderate (F2, ≥7.7 to <9.8)
nd severe (F3-4, ≥9.8) [17]. APRI is calculated according to the for-
ula (AST [U/l] × 100)/(ULNAST × platelet count [109/l]) [16]. The
ST-upper limit of normal in our laboratory is 35 U/l for males
nd 31 U/l for females, respectively. APRI uses different cut-offs for
brosis and cirrhosis: the existence of severe ﬁbrosis is unlikely for
PRI ≤0.7 and cirrhosis is likely for APRI ≥1.0 [9,16,18].
All patients were instructed not to drink or eat prior to blood
ollection and ultrasound measurement. Thus we used fasted blood
amples and ultrasound measurements.
.3. LSM by transient elastography
Liver stiffness was measured by a trained nurse or physician
sing a FibroScan® instrument (EchosensTM, Paris, France) at the
ame time points as for serum marker determination. Only those
easurements with more than ten successful acquisitions, with auccess rate (successful measurements × 100/all measurements) of
t least 60% and an interquartile range lower than 30%, were classi-
ed as valid and taken into consideration for statistical evaluation
19]. All LSM values relate to the validated liver ﬁbrosis METAVIR
brosis stages with the following cut-off values: <7.1 kPa = F0-1,
.1–9.6 kPa = F2, 9.6–11.6 kPa = F3, ≥11.6 kPa = F4 [19].r Disease 48 (2016) 291–297
2.4. Biochemical, virological and metabolic response
The biochemical response to therapy (ALT, AST, GT,  bilirubin),
viral load (HCV-RNA), parameters of lipid and iron metabolism and
insulin resistance were assessed at weeks 0, 4, EoT, and SVR12. We
deﬁned biochemical response as a normalization of ALT (<35 IU/l
for male and <31 IU/l for female patients). And virological response
was interpreted as indicative of the absence of detectable HCV-RNA
at time point SVR12.
The lower limit of HCV-RNA detection is 10 IU/ml in our lab-
oratory (COBAS TaqMan HCV test, version 2.0, Roche Diagnostics
AG, Rotkreuz, Switzerland; lower limit of quantiﬁcation: 25 IU/ml;
lower limit of detection: 10 IU/ml). All clinical chemical parame-
ters were measured by the Central Laboratory of Mainz University
Medical Centre. As a non-invasive marker for insulin resistance, we
used the computerized calculated HOMA-IR 2 (Homeostasis Model
Assessment-insulin resistance), which is calculated from fasting
plasma glucose and insulin using the “HOMA Calculator” (©The Uni-
versity of Oxford 2013) [20,21]. For values <1.4 insulin resistance
is unlikely [21].
2.5. Statistical analysis
Owing to the skewed distribution of the parameters used for
the ELF-score and APRI, serum biomarkers of hepatic function,
clinical chemistry and liver stiffness, data are given as medians
with corresponding inter quartile ranges and shown graphically
by box-and-whiskers plots. Pairwise comparisons of biomarkers,
ELF-score, APRI and LSM between the baseline and SVR12 were
conducted using the nonparametric Wilcoxon signed-rank test.
Presented correlations were calculated using the Spearman rank-
order correlation (rS).
The main objective of this study is to examine the differences
between baseline and SVR12 concerning the three variables ELF,
APRI and LSM. p-values were given for descriptive reasons only
and should be considered with caution.
All statistical analyses were performed using SPSS Version 22
(SPSS Inc., Chicago, Illinois, USA).
3. Results
A total of 46 patients were initially screened, and 11 were
excluded due to incomplete clinical data, blood tests or study visits
at more than one time point. An additional three subjects had to be
excluded because of obesity (BMI 35–40 kg/m2), making valid LSM
data unavailable. Therefore, 32 patients treated until SVR12 were
eligible for analysis.
The median age of participants was  55 years (49–58); 56% were
male. A total of 20 patients showed mild to moderate ﬁbrosis at
the baseline (≤F2) and 11 severe ﬁbrosis or cirrhosis (≥F3) cate-
gorized by LSM (one LSM (3.1%) showed invalid measurements). A
total of 10 patients had compensated cirrhosis (F4; LSM >11.6 kPa)
with median MELD = 9 (6.0–10.3), 126 platelets/l (88.3–193.0)
and Child–Pugh class A at the baseline. In nine out of 10 patients,
cirrhosis was  conﬁrmed by the ELF-score (rS = 0.976, p < 0.001).
All patients were treated with sofosbuvir, 19 in combination
with PEG-IFN, 29 in combination with RBV and four in combination
with simeprevir. Patient characteristics and key laboratory values
at the baseline are presented in Table 1.
Twenty eight patients (87.5%) underwent 12-week therapy.
Only four were treated for 24 weeks. Three of those patients
received RBV and sofosbuvir and one RBV, sofosbuvir and PEG-
IFN. In the subgroup analysis for the patients treated for 24 weeks
exhibited no signiﬁcant changes because of the very small subgroup
size.
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Fig. 1. Enhanced liver ﬁbrosis score and its single component parameters at weeks 0, 4, end of treatment and 12-week follow-up. Median decrease for (A) enhanced liver
ﬁbrosis-score from 10.00 to 9.37 (baseline vs. 12-week follow-up); (B) hyaluronic acid from 68.7 to 50.4 ng/ml; (C) N-terminal propeptide of type III procollagen from 9.5 to
6.8  ng/ml; (D) tissue inhibitor of metalloproteinase-1 from 289.9 to 250.3 ng/ml; outliers are as indicated; p values are for the comparison between baseline and 12-week
follow-up. ELF, enhanced liver ﬁbrosis; EoT, end of treatment; SVR, sustained virological response; SVR12, 12-week post-treatment follow-up; HA, hyaluronic acid; PIIINP,
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niﬁcantly decreased from 8 kPa (METAVIR F2) at baseline to 6.8 kPa
(METAVIR F0-1) at SVR12 (p = 0.016) (Fig. 2) [19].
For patients with severe ﬁbrosis or cirrhosis, a decrease of LSM
by 24% was achieved, resulting in a conversion of the median of-terminal propeptide of type III procollagen; TIMP1, tissue inhibitor of metallopro
The SVR12 rate was 93.8% with only 2/32 patients experiencing
 relapse at 12 weeks of follow-up; all end-of-follow-up data is
xpressed as “SVR12”.
.1. Fibrosis markers
The ELF-score declined signiﬁcantly from the baseline to SVR12
10.00 to 9.37, p = 0.007). With the chosen cut-offs, the median
hanged from the category of severe ﬁbrosis (ELF > 9.8) to the cat-
gory of moderate ﬁbrosis (≥7.7 to <9.8; Fig. 1).
All single component parameters of the ELF-score decreased at
VR12 compared to baseline: this was for HA and TIMP-1 (p = 0.002
nd p = 0.004, Fig. 1). An important decline of PIIINP was not
etectable (p = 0.093). Supplementary Figure S1 illustrates the indi-
idual course of every patient for ELF, HA, PIIINP and TIMP-1.
Notably, HA increased 2.5-fold from the baseline to week 4
p = 0.003), reaching a maximum median level of 170.8 ng/ml, while
lterations to PIIINP and TIMP-1 levels were not relevant. Separated
y PEG-IFN treatment, the group with PEG-IFN showed a threefold
ncrease of HA from the baseline to week four (59.5–177.9 mg/ml,
 = 0.002), whereas in patients without PEG-IFN there was a
ild decrease from the baseline to week 4 (169.1–145.9 mg/ml, = 0.859, Supplementary Figure S2).
According to HA levels, liver stiffness increased at week 4 vs.
aseline (median 12.9 kPa, suggestive of METAVIR F4 vs. 8.0 kPa;
uggestive of METAVIR F2) but with high variance (p = 0.387).e-1.
The median of the LSM over the whole observation period sig-Fig. 2. Liver stiffness measurement at weeks 0, 4, end of treatment, 12-week follow-
up; median decrease from 8.0 kPa to 6.8 kPa. LSM, liver stiffness measurement;
EoT, end of treatment; SVR, sustained virological response; SVR12, 12-week post-
treatment follow-up.
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Table  1
Patient demographics at baseline.
Characteristics
N 32
Males 18 (56.3%)
Age 54.5 years (49–58)
BMI 23.5 kg/m2 (22.4–28.6)
HCV genotype
1 22 (68.8%)
2 6 (18.8%)
3 3 (9.4%)
4 1 (3.1%)
Stage of ﬁbrosis
Data missing 1 (3.1%)
≤2 20 (62.5%)
≥3 11 (34.4%)
Peginterferon 19 (59.4%)
Diabetes 2 (6.2%)
Previous antiviral treatment 15 (46.9%)
HCV-RNA 1.7 × 106 IU/ml (1.2 × 106–1.8 × 106)
Coinfection
HIV 1 (3.1%)
Chronic hepatitis B 1 (3.1%)
Bilirubin 0.91 mg/dl (0.80–0.98)
Creatinine 0.82 mg/dl (0.79–0.88)
ALT 59.0 U/l (50.0–80.5)
AST 51.0 U/l (44.5–63.0)
GT  64.5 U/l (45.1–90.0)
Albumin 39.0 g/l (39.0–39.0)
Liver stiffness measurement 8.0 kPa (6.7–9.5)
APRI 0.96 (0.72–1.26)
LDL cholesterol 74.0 mg/dl (62.0–115.0)
HDL cholesterol 51.0 mg/dl (39.0–57.0)
HbA1c 5.3% (5.2–5.5)
Ferritin 200.0 ng/ml (130.0–251.0)
Serum iron 125.0 g/dl (118.0–138.0)
Continuous data are given as median (inter quartile range).
BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; HIV, human
immunodeﬁciency virus; ALT, aspartate aminotransferase; AST, aspartate amino-
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rransferase; APRI, AST/platelet-ratio-index; LDL, low density lipoprotein; HDL, high
ensity lipoprotein.
irrhosis (median: 15.1 kPa; METAVIR: F4) into advanced ﬁbrosis
median: 11.5 kPa; METAVIR: F3), p = 0.018. All cirrhotics have sim-
lar values at baseline and SVR12 for MELD-score (9.0 to 9.0) and
latelets (126/nl to 125/nl).Similarly, the decrease of APRI from baseline to SVR12
as highly signiﬁcant (p < 0.001, Fig. 3). Thus, with a median
ig. 3. Aspartate aminotransferase/platelet-ratio-index-scores at weeks 0, 4, end
f treatment and 12-week follow-up; median decrease from 0.96 to 0.50.
PRI, AST/platelet-ratio-index; EoT, end of treatment; SVR, sustained virological
esponse; SVR12, 12-week post-treatment follow-up.r Disease 48 (2016) 291–297
APRI = 0.5 at the end of treatment, the overall group was  classiﬁed
as non-cirrhotic [18].
3.2. Biochemical response
The biochemical response to therapy is shown in Fig. 4. In partic-
ular, the serum activities for ALT, AST and GT normalized at SVR12
compared to baseline (p < 0.001). Total bilirubin also decreased
from the baseline upper normal values (0.91 mg/dl) to 0.74 mg/dl
(p = 0.034).
Regarding metabolic parameters, the median for HOMA-IR2 was
2.71 at baseline (two patients showed no insulin resistance) and
2.23 at SVR 12 (5 patients had no insulin resistance). Both values
are above the cut-off of 1.4, indicating low level insulin resistance,
with no detectable improvement during the observation period
(p = 0.345), Table 2 [20].
All values in the cholesterol levels (total cholesterol, LDL-
cholesterol, HDL-cholesterol, LDL/HDL-ratio and triglycerides) did
not reach relevant changes. Total cholesterol shows a decrease
under therapy and an increase above the baseline level after EoT.
LDL increased during and after treatment, HDL showed a mild
decrease and triglycerides rise moderately at EoT and SVR12 com-
pared to baseline (Table 2).
There was  a reduction in serum ferritin levels from baseline
(195 ng/ml) to SVR12 (80 ng/ml, p < 0.001), indicating a decrease
within the reference range, similar to bilirubin. Serum iron
decreased from 123.0 g/dl to 103.0 g/dl (p = 0.117). Also, trans-
ferrin saturation showed normal values at both time points
(baseline = 28.9% and SVR12 = 27.3%, respectively) and therefore
decreased by 5.5% (p = 0.071). Transferrin increased from 2.81 to
2.97 g/l (p = 0.583).
4. Discussion
This is the ﬁrst study investigating the effects of a sofosbuvir-
based, highly efﬁcient antiviral therapy for CHC  on early changes in
parameters of liver ﬁbrosis progression. The non-invasive serologi-
cal and ultrasound-based markers ELF and LSM suggest a signiﬁcant
regression of liver ﬁbrosis at SVR12 compared to baseline. Previ-
ously, all non-invasive markers were shown to correlate well with
of liver ﬁbrosis stage and possibly ﬁbrogenesis in CHC [6–9,14,16].
LSM especially was demonstrated in clinical studies as a useful tool
for assessment of the clinical effects of HCV treatment [10–13].
Notably, the quantity of change was impressive, since all three tests
were comparable to at least one stage decrease in the METAVIR
ﬁbrosis stage at SVR12 in the median. Thus, the ELF-score median
fell from severe to moderate ﬁbrosis (p = 0.007), the APRI in median
dropped below the cut-off for severe ﬁbrosis (p < 0.001), and LSM
(FibroScan®) showed a ﬁbrosis stage of F0-1 at SVR12 in the median
of all patients (p = 0.016). Changes of APRI may  be primarily affected
by the reduction of AST levels and are directly inﬂuenced by hepatic
inﬂammation. The LSM by FibroScan® might also be inﬂuenced by
inﬂammation, which has been conﬁrmed in patients with chronic
hepatitis B [22].
Therefore, we additionally assessed the impact of antiviral ther-
apy on the ELF-score, which is considered the best serum test for the
non-invasive measurement of liver ﬁbrosis. The ELF-panel of direct
(matrix-derived) serum markers is based on an algorithm of age,
serum procollagen type III amino terminal propeptide (PIIINP), tis-
sue inhibitor of metalloproteinases-1 (TIMP-1) and hyaluronic acid
(HA) [15,23,24]. The ELF panel might serve as a predictive marker
of liver ﬁbrosis progression/regression rather than static ﬁbrosis
stage. This is suggested by the nature of the markers in this panel
(PIIINP, TIMP-1, hyaluronic acid), which should instead relate to
the dynamics of ﬁbrogenesis, i.e., de novo scar tissue deposition
[25,26]. Sequential biopsies and long-term follow-up of patients
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Fig. 4. Markers of liver injury at weeks 0, 4, End of treatment and 12-week follow-up, median decrease of (A) alanine aminotransferase from 59.0 to 24.0 U/l; (B) aspartate
aminotransferase from 54.0 to 27.0 U/l; (C) gamma-glutamyl transpeptidase from 64.5 to 24.0 U/l; (D) bilirubin from 0.91 to 0.74 mg/dl. ALT, alanine aminotransferase; AST,
aspartate aminotransferase; GT, gamma-glutamyl transpeptidase; EoT, snd of treatment; SVR, sustained virological response; SVR12, 12-week post-treatment follow-up.
Table 2
Glucose, iron and lipid metabolism levels at study time points in 32 patients treated with sofosbuvir-based regimens.
Unit Baseline Week 4 EoT SVR12 p-value
Glucose mg/dl 90.0 (81.0–115.0) 93.0 (84.0–107.5) 92.0 (83.0–96.0) 99.0 (90.3–114.5) 0.066
Insulin mU/l 11.8 (5.5–22.5) 15.4 (12.3–25.8) 15.2 (8.0–20.9) 13.4 (8.0–17.4) 0.455
C-Peptide ng/ml 3.7 (2.2–6.0) 3.8 (2.3–4.4) 3.4 (2.2–4.0) 3.1 (2.0–3.7) 0.686
HOMA-IR2 2.71 (1.48–4.99) 2.53 (1.69–3.13) 2.23 (1.62–3.00) 2.23 (1.44–2.82) 0.345
Serum iron g/ml 123.0 (85.0–145.0) 148.5 (79.3–204.8) 98.5 (86.3–167.3) 103.0 (79.0–123.3) 0.117
Ferritin ng/ml 195.0 (80.8–333.8) 182.5 (54.5–382.5) 328.0 (92.0–655.0) 80.0 (35.0–138.5) <0.001
Transferrin g/l 2.81 (2.41–3.24) 2.77 (1.95–3.64) 2.53 (2.13–3.17) 2.97 (2.38–3.35) 0.583
Transferrin saturation % 28.9 (22.7–41.0) 36.6 (20.5–66.4) 31.4 (22.9–40.3) 27.3 (17.9–34.0) 0.071
Total  cholesterol mg/dl 165.5 (118.8–186.3) 137.0 (110.3–178.8) 157.5 (113.5–174.0) 184.0 (167.8–206.8) 0.168
LDL  cholesterol mg/dl 72.0 (59.0–117.5) 70.0 (57.0–100.0) 95.0 (63.0–107.0) 117.0 (75.8–136.3) 0.059
HDL  cholesterol mg/dl 51.0 (37.0–59.5) 45.0 (36.0–56.0) 40.0 (35.0–56.0) 45.5 (35.5–54.8) 0.514
Triglycerides mg/dl 97.0 (83.5–146.5) 87.0 (58.8–156.3) 105.0 (70.8–155.8) 110.0 (77.0–182.0) 0.248
Continuous variables data are given as medians (interquartile range).
p-values apply to week 0 and SVR12.
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A successful antiviral therapy results in a lower risk of HCC, a
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The SVR rate in our group was 93.8%, which is higher compared
o other cohorts, but we have no good explanation for these sur-
rising results in our actual clinical practice.esponse at 12-week follow-up; HOMA-IR, homeostasis model assessment-insulin
re given as median (inter quartile range).
There was  a non-signiﬁcant increase in LSM at week 4. One
possible explanation is that patients did not fast prior to measure-
ment. But all patients were instructed not to drink or eat prior to
blood collection and ultrasound measurement. However, it is more
likely that increased liver blood ﬂow by RBV induced anaemia and a
higher cardiac output, hence the reasons in higher LSM values [29].
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 to 4 (p = 0.387). The correlation between changes in LSM and Hb
rom the baseline to week 4 is relevant (rS = −0.230) but not statis-
ically signiﬁcant (p = 0.317) (Supplementary Figure S3). The same
nalysis for baseline and EoT is shown in Supplementary Figure
4. The results are similar to the analysis of baseline to week 4 with
S = −0.503 (p = 0.079). Hb decreased by 17.3% (15.0 g/dl to 12.4 g/dl;
 < 0.001) and LSM increased by 15.8% (p = 0.247).
Interestingly, in the beginning, the ELF-score increased from
he baseline to week 4 from 10.00 to 10.89 (p = 0.003), which
as due solely to a transient rise in the component parame-
er HA from week 0 to week 4 (68.7 to 170.8 ng/ml), while the
ther two markers remained widely unchanged. Increase in HA
evels was also reported at prior studies [29,30]. HA is an acidic
olysaccharide with a short serum half-life that is rapidly cleared
rom circulation mainly by hepatic sinusoidal endothelial cells
31,32]. HA in its polymeric variants exerts multiple functions,
ncluding the regulation of cell adhesion, inﬂammatory cell recruit-
ent, release of pro-inﬂammatory cytokines, and cell migration
33]. CHC induces a generalized inﬂammatory response in the
iver, including the sinusoidal endothelium [34]. While the rea-
on for the transient increase in HA at the beginning of antiviral
herapy needs further investigation, one could speculate that the
econstitution of the Th1 T cell response to HCV by highly efﬁ-
ient therapy affects not only the extracellular matrix, including
ts remodelling and degradation, which may  be reﬂected by the
ise of HA in serum, but also transiently increases the inﬂam-
atory inﬁltrate. This could also explain the increase in liver
tiffness at week 4 [35]. A second possible explanation for this
bservation is the effect of PEG-IFN. Subgroup analysis by PEG-
FN therapy shows an impressive increase of HA from baseline
o week 4 only in patients treated with PEG-IFN (p = 0.002) in
ontrast to a mild decrease in patients not subject to the same
reatment (p = 0.859) (Supplementary Figure S2). This effect can
e explained by proinﬂammatory activities of the cytokine inter-
eron and the possible reduction of uptake of HA by endothelial liver
ells [29].
All three non-invasive markers, particularly the thresholds for
1, F2, F3 and F4, were evaluated in patients who are in a steady
tate of inﬂammatory liver disease. Thus, we can show the reduc-
ion in hepatic inﬂammation and give a positive predictor for liver
brosis regression.
The non-invasive markers ELF and especially LSM may  be
nﬂuenced by portal pressure. This possibly affects the diagnostic
ccuracy of the biomarkers and LSM. Consequently, further studies
o examine the correlation between treatment response, ﬁbrosis
arkers and portal pressure are necessary.
Two of the 32 patients with CHC had no insulin resistance at
aseline, as measured by HOMA-IR2; at time point SVR12 this
umber increased to 5 (15.6%). Prior studies have reported an
mprovement in insulin resistance during treatment, highlighting
he correlation between viral eradication and insulin resistance
36–38]. However, the plasma glucose level, which is part of the
OMA-IR2, may  have been affected by RBV-mediated haemolysis.
lso, major parameters of lipid metabolism remained unchanged
y antiviral therapy, though HCV partially interacts with LDL
eceptors when entering the cell and is important for viral repli-
ation, suggesting a role of lipids in regulation of HCV clearance
39,40]. To answer the questions about changes in glucose and
ipid metabolism, further studies more patients, longer follow-up
eriods and more reﬁned analyses, e.g. for lipid particle subfrac-
ions, are required.
Values for total cholesterol, LDL and triglycerides showed no
elevant changes. Also, prior studies of changes in lipid proﬁles
uring HCV therapy with sofosbuvir or PEG-IFN and RBV reported
nconsistent results [36,41,42]. For example, Meissner et al. demon-
trated signiﬁcant variation in triglyceride levels [36], but Langer Disease 48 (2016) 291–297
et al. and Jung et al. conﬁrmed the insigniﬁcance of these results
[41,42].
Ferritin, as an iron storage and acute phase protein, ranged
within normal values at the baseline and declined by almost 60%
at SVR12 (p < 0.001). Also, transferrin saturation showed values
in the reference range at both time points, with a decrease by
5.5% (p = 0.071). This suggests that there is no real iron overload,
but the changes in ferritin and transferrin saturation might be
explained by the improvement in virus-induced hepatic inﬂam-
mation. Other parameters of iron metabolism (serum iron and
transferrin) showed no relevant changes.
The liver enzymes (ALT, AST and GT) rapidly normalized
under treatment. Bilirubin, which was already in the normal range
(0.91 mg/dl) before therapy, decreased to 0.74 mg/dl at SVR12, pro-
viding additional evidence for the improvement in liver function by
highly effective antiviral therapy.
Overall, seven patients presented with elevated liver enzymes
at SVR12 (22%).
Of these seven patients, three had concomitant NASH and two
had cirrhosis. One of the remaining two patients presented with
relapse. In one case, the reason for the elevated liver enzymes
remained unknown.
A limitation of this study is that it was not possible to perform
protocol liver biopsies because of the short duration of treatment
and, thus, ethical concerns. Although we  were not able to quantify
liver ﬁbrosis histologically by METAVIR score, the three indepen-
dent serological and ultrasound-based tests for the assessment of
ﬁbrosis during antiviral therapy suggested a congruent, signiﬁcant
improvement of ﬁbrosis. Therefore, a continuous ELF- or LSM-
derived scoring of ﬁbrosis could provide a more robust assessment
of the dynamic changes associated with ﬁbrosis than modelling
against the categorical METAVIR score as suggested for metabolic
proﬁling (i.e., LDL) by Sands et al. [43].
In conclusion, this is the ﬁrst study implying signiﬁcant and
clinically relevant reduction in liver ﬁbrosis measures by three
independent non-invasive predictors for liver ﬁbrosis assessment
(ELF, APRI) and liver stiffness measurement under highly effec-
tive antiviral regimens with sofosbuvir. Despite the relatively small
sample size, the effects on ﬁbrosis parameters are impressive,
implying clinically signiﬁcant ﬁbrosis regression and potential
reduction of cirrhosis-associated mortality in successfully treated
patients with CHC.
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